When was Engine Biosciences founded?

Engine Biosciences was founded in 2014 and raised its 1st funding round 4 years after it was founded.

Where is Engine Biosciences located?

Engine Biosciences is headquartered in Singapore, Singapore. It is registered at San Carlos, California.

Which legal entities is Engine Biosciences associated with?

Engine Biosciences is associated with Engine Biosciences Pte. Ltd and 1 other.

How many employees does Engine Biosciences have?

As of Jul 31, 2026, the latest employee count at Engine Biosciences is 36.

Is Engine Biosciences a funded company?

Engine Biosciences is a funded company, having raised a total of $86M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jan 31, 2018.

When was the latest funding round of Engine Biosciences?

Engine Biosciences' latest funding was a $***** Series A round on Oct 31, 2023, with participation from 6 investors.

Where does Engine Biosciences rank among its competitors?

Engine Biosciences ranks 57th amongst 2128 active competitors, of which 512 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Antheia, which secured $24M in Jan, 2026.

Who are the top competitors of Engine Biosciences?

Engine Biosciences' top competitors include DNAnexus, Insitro and Antheia. Among them, Antheia secured the most recent funding round in January, 2026.

Engine Biosciences - 2026 Company Profile, Team, Funding, Competitors & Financials

Engine Biosciences is a series A company based in Singapore (Singapore), founded in 2014 by Yaron Turpaz. It operates as a Developer of platform technology for combinatorial genetics discovery. Engine Biosciences has raised $86M in funding from investors like Polaris Partners, DHVC and 6 Dimensions Capital. The company has 2128 active competitors, including 512 funded and 326 that have exited. Its top competitors include companies like DNAnexus, Insitro and Antheia.

Company Details

Developer of platform technology for combinatorial genetics discovery. The company's platform technology for the discovery of novel gene and drug combinations for therapeutic and industrial biotechnology applications. The company's technology allows for ultra-high-throughput screens and the discovery of combinatorial genes and drugs with effects on targeted phenotypes.

Website: www.enginebio.com/
Registered Address: San Carlos, California

Key Metrics

Founded Year

2014

Location

Singapore, Singapore

Stage

Series A

Total Funding

$86M in 3 rounds

Latest Funding Round

Series A, Oct 31, 2023, $*****

Investors

Polaris Partners & 19 more

Ranked

57^th among 2128 active competitors

Employee Count

36 as on Jul 31, 2026

Similar Companies

DNAnexus & 2859 more

View Engine Biosciences' full profile

Engine Biosciences is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
ENGINE BIOSCIENCES, INC. CIN: 823478285 , United States, Active	Dec 26, 999	-	5 (As on Dec 31, 2024)	-
Engine Biosciences Pte. Ltd CIN: 201438228E , Singapore, Active	Dec 31, 2013	-	-

Engine Biosciences has raised a total funding of $86M over 3 rounds. Its first funding round was on Jan 31, 2018. Its latest funding round was a Series A round on Oct 31, 2023 for $*****. 6 investors participated in its latest round. Engine Biosciences has 20 institutional investors.

Here is the list of recent funding rounds of Engine Biosciences:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 31, 2023	1191552	Series A	5525337	2321181	3962456	1397510
May 26, 2021	9289115	Series A	9514432	8537824	2727185	Invus & 9 more
Jan 31, 2018	3870616	Seed	6260559	7990356	6 Dimensions Capital & 1 more	WuXi AppTec & 5 more

Access funding benchmarks and valuations. Sign up today!

View details of Engine Biosciences's funding rounds and investors

The founders of Engine Biosciences is Yaron Turpaz.

Here are the details of Engine Biosciences' key team members:

Yaron Turpaz: Co-Founder and Board Member of Engine Biosciences.

Engine Biosciences' Board of Directors

Engine Biosciences's board has 5 active members. Jeffrey Lui is part of team and Timothy Tan, Ho Wen Qi, Amy Weinfeld Schulman and Ali Farahani are independent board members.

Here is the list of Engine Biosciences' board of directors:

Name	Type	Representing	Status	Duration
Jeffrey Lui	Team	-	Current	11y 8m
Timothy Tan	Independent board member	-	Current	11y 8m
kaxfvhv	Independent board member	-	Current	6y 5m
lqzmf{z	Independent board member	-	Current	2y 3m
etkjxbr	Independent board member	-	Current	5y 3m
mohsupc	Independent board member	-	Past	2y 6m
czlkwmi	Independent board member	-	Past	6y 2m
myucoeh	Independent board member	-	Past	9y 4m

View details of Engine Biosciences's Founder profiles and Board Members

Engine Biosciences' employee count trend

Engine Biosciences has 36 employees as of Jul 26. Here is Engine Biosciences's employee count trend over the years:

Employee count trend for Engine Biosciences

Uncover Engine Biosciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Engine Biosciences include DNAnexus, Insitro and Antheia. Here is the list of Top 10 competitors of Engine Biosciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	DNAnexus 2009, Mountain View (United States), Series H	Provider of cloud-based genome informatics & data management platform	$473M	Google Ventures, TPG & 21 others	71/100
2nd	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
3rd	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
4th	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, Temasek & 11 others	66/100
5th	Immunai Technologies 2018, United States, Series B	Developer of next-generation of immunomodulatory therapeutics	$295M	Catalio Capital Management, Koch Disruptive Technologies ... & 14 others	65/100
6th	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Loayal Valley Capital, Sino Biopharmaceutical ... & 18 others	65/100
7th	Asimov 2017, Boston (United States), Series B	Provider of integrated suite for advanced genetic design and manufacturing	$234M	Andreessen Horowitz, Horizons Ventures & 11 others	65/100
8th	Metagenomi 2016, Berkeley (United States), Public	Digital gene editing technologies for drug development	$376M	Humboldt Fund, RA Capital Management & 22 others	64/100
9th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Cormorant Asset Management, Atlas Venture ... & 14 others	64/100
10th	Relation 2019, London (United Kingdom), Seed	AI-based drug development tools for researchers	$116M	DCVC, Magnetic Ventures & 9 others	64/100
57th	Engine Biosciences 2014, Singapore (Singapore), Series A	Developer of platform technology for combinatorial genetics discovery	$86M	DHVC, Invus & 18 others	56/100